Redirected cells with mhc chimeric receptors and methods of use in immunotherapy

ABSTRACT

Chimeric receptors featuring major histocompatibility molecules grafted onto T cell receptor molecules and surrogate co-receptors featuring cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be used to redirect cells, altering their specificity. T cells expressing chimeric receptors may bind to TCRs of target T cells for which their chimeric receptors are specific. Surrogate co-receptors may be used to help enhance TCR-CD3 signaling as part of this modular receptor system. The chimeric receptors and surrogate coreceptors may be used to help eliminate autoreactive T cells or program T cells to desired effector functions.

CROSS REFERENCE

This application is a Divisional and claims benefit of U.S. patent application Ser. No. 15/738,467 filed Dec. 20, 2017 which is a 371 application and claims benefit of International Patent Application No. PCT/US16/40177 filed Jun. 29, 2016, which claims benefit of U.S. Provisional Patent Application No. 62/186,865 filed Jun. 30, 2015, the specification(s) of which is/are incorporated herein in their entirety by reference.

GOVERNMENT SUPPORT

This invention was made with government support under Grant No. R01 AI101053 awarded by NIH. The government has certain rights in the invention.

REFERENCE TO SEQUENCE LISTING

Applicant asserts that the paper copy of the Sequence Listing is identical to the Sequence Listing in computer readable form found on the accompanying computer file, entitled UNIA_15_04_PCT_US_DIV_Sequence_Listing_ST25, and is identical to that forming part of the international application as filed. The content of the sequence listing is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to T cells and T cell receptors, more particularly to redirected T cells with engineered receptors, more particularly to redirected cells expressing a chimeric receptor comprising a major histocompatibility complex (MHC) molecule, including redirected cells further comprising a surrogate coreceptor, e.g., as components of a modular chimeric receptor system.

BACKGROUND OF THE INVENTION

T cells normally recognize and respond to peptide antigens embedded within major histocompatibility complex molecules (pMHCs) of antigen presenting cells (APCs) via their TCR-CD3 complex (see FIG. 1A). This eight-subunit TCR-CD3 complex is composed of the TCR, which is the receptor module that binds the pMHC, and the CD3γε, CD3δε, and CD3ζζ signaling modules that connect the TCR to the intracellular signaling machinery (see FIG. 1B). The intracellular domains of the CD3 subunits contain immunoreceptor tyrosine-based activation motifs (ITAMs) that are phosphorylated by the Src kinases, e.g., Lck, Fyn. CD3γ, CD3δ, and CD3ε each contain one ITAM while CD3ζ contains three ITAMs for a total of ten in a single complex. The TCR-CD3 complex does not appear to have any intrinsic Src kinase activity. In fact, coreceptors (e.g., CD4, CD8) appear to sequester Lck away from the TCR-CD3 complex until both a coreceptor and a TCR bind a pMHC. The Lck associated with the coreceptor is then brought into close proximity to the CD3 ITAMs to phosphorylate tyrosines within these motifs and initiate signaling.

Ectopic T cell receptors (TCRs) have been introduced into T cells in an effort to reprogram or alter T cell specificity. However, in some cases, the introduction of ectopic TCRs has been found to lead to cross-pairing events with endogenous TCRs, resulting in novel TCRs with autoimmune specificities. This lead to the use of chimeric antigen receptors (CARs), which are typically designed with (a) an extracellular domain consisting of a single-chain variable fragment (scFv) of a monoclonal antibody directed against a target antigen; (b) a transmembrane domain that does not mediate interactions with other protein subunits; and (c) an intracellular domain consisting of the CD3ζ intracellular signaling domain as well as signaling domains from a variety of other signaling molecules (e.g., CD28, CD27, ICOS, 4-1BB, OX40). Without wishing to limit the present invention to any theory or mechanism, it is believed that CARs do not sufficiently take advantage of the modularity of the existing signaling apparatus, which is optimized to direct T cell activation and effector functions. CARs are likely to be delivering incomplete signals that could have unintended consequences or side effects.

The present invention features novel chimeric receptors (e.g., “MHCRs”) comprising a portion of a MHC molecule (e.g., class I, class II, non-classical MHC) and a portion of the TCR. In some embodiments, the MHCR comprises a portion of an antigen peptide. The present invention also features cells, such as T cells, expressing said MHCRs (cells expressing a MHCR are herein referred to as “redirected cells”). The MHCRs are adapted to recognize and bind to appropriate (specific) TCRs. Redirected cells (e.g., redirected T cells) expressing a MHCR would mimic antigen presenting cells (APCs), the cells that normally express MHC molecules. In some cases, binding of a TCR of a target T cell to the MHCR of the redirected cell may then result in destruction of the target T cell; thus, in this case, the redirected cells may function as “anti-T cell” T cells. The present invention is not limited to redirected cells functioning to destroy a target. For example, in some embodiments, the redirected cell is adapted to help reprogram a target cell, e.g., the redirected cell may deliver instructions to the target cell.

The present invention also features engineered cells expressing both an MHCR and an SCR. It was surprisingly discovered that engineered cells co-expressing an MHCR and an SCR had enhanced effects (e.g., increased IL-2 expression, see FIG. 5) as compared to engineered cells expressing a MHCR without co-expression of an SCR. Without wishing to limit the present invention to any theory or mechanism, it is believed that the use of an SCR in combination with a MHCR enhances signaling and/or other downstream effects. Without wishing to limit the present invention to any theory or mechanism, it is believed that the combination of the MHCR and SCR may provide a synergistic effect, e.g., effects of the combination of the MHCR and SCR may provide effects greater than those of the MHCR and SCR individually.

Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.

SUMMARY OF THE INVENTION

The present invention features novel chimeric receptors for engineering redirected cells. For example, the present invention features an engineered cell co-expressing on its surface a chimeric receptor (MHCR) comprising a major histocompatibility complex (MHC) portion (derived from a MHC protein) directly or indirectly fused to a T cell receptor (TCR) portion (derived from a TCR protein); and a surrogate co-receptor (SCR) comprising a cell surface receptor ligand portion directly or indirectly fused to a signaling molecule portion. In some embodiments, the MHCR is adapted to bind to a TCR of a target cell and the SCR is adapted to bind to a cell surface receptor of the target cell. In some embodiments, binding of the MHCR to the TCR of the target cell and binding of the SCR to the cell surface receptor of the target cell (i) initiates a signaling cascade effective for eliminating the target cell or (ii) instructs the target cell to differentiate to a specific effector function. In some embodiments, the cell (e.g., genetically engineered cell) is a T cell (e.g., CD4+, CD8+); however, the present invention is not limited to T cells.

In some embodiments, the TCR portion comprises a transmembrane domain of the TCR protein and the MHC portion comprises an extracellular domain of the MHC protein. In some embodiments, the TCR portion comprises at least a portion of a transmembrane domain of the TCR protein and the MHC portion comprises at least a portion of an extracellular domain of the MHC protein. In some embodiments, the TCR portion comprises at least a portion of a transmembrane domain and at least a portion of a cytoplasmic domain of a TCR protein, and the MHC portion comprises at least a portion of an extracellular domain of the MHC protein.

In some embodiments, the MHC portion of the MHCR is N-terminal to the TCR portion of the MHCR. In some embodiments, the MHC portion is directly fused to the TCR portion. In some embodiments, the MHC portion is indirectly fused to the TCR portion via a linker. In some embodiments, the MHCR further comprises a peptide antigen integrated into the MHC portion, or directly or indirectly fused to the MHC portion. In some embodiments, the peptide antigen is linked to the MHC portion via a linker. In some embodiments, the linker comprises a glycine-rich peptide. In some embodiments, the SCR further comprises a transmembrane domain positioned in between the cell surface receptor ligand portion and the signaling molecule portion. In some embodiments, the MHC protein, the TCR protein, or both the MHC protein and the TCR protein are mammalian proteins (e.g., human, mouse, cat, dog, etc. In some embodiments, the signaling molecule portion has kinase or phosphatase activity. In some embodiments, the signaling molecule portion comprises a Src kinase.

In some embodiments, the MHC protein comprises HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB beta, H2-EK alpha, H2-EK beta, a fragment thereof, or a combination thereof. In some embodiments, the MHC molecule comprises HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB beta, H2-EK alpha, H2-EK beta, a peptide that is at least 90% identical to HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB beta, H2-EK alpha, or H2-EK beta, a fragment thereof, or a combination thereof. In some embodiments, the TCR molecule comprises TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, TCC4, a fragment thereof, or a combination thereof. In some embodiments, the TCR molecule comprises TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, TCC4, a peptide that is at least 90% identical to TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, or TCC4, a fragment thereof, or a combination thereof. In some embodiments, the cell surface receptor ligand portion of the SCR comprises a CD28 ligand, a CTLA-4 ligand, an ICOS ligand, an OX40 ligand, a PD-1 ligand, or a CD2 ligand. In some embodiments, the CD28 ligand comprises CD80, CD86, or both CD80 and CD86. In some embodiments, the MHCR is adapted to complex with a CD3 subunit. In some embodiments, the engineered cell further co-expresses a second SCR.

The present invention also features a chimeric receptor (MHCR) as described above. For example, the MHCR may comprise a major histocompatibility complex (MHC) portion derived from a MHC protein directly or indirectly fused to a T cell receptor (TCR) portion derived from a TCR protein, wherein the MHCR is adapted to bind to a TCR of a target cell.

The present invention also features a method of eliminating a target cell or reprogramming a target cell (the target cell comprising a TCR). In some embodiments, the method comprises introducing a genetically engineered cell that expresses on its surface a chimeric receptor (MHCR) according to the present invention to the target cell, wherein the MHCR is specific for the TCR of the target cell, wherein upon binding of the MHCR to the TCR the genetically engineered cell (a) initiates a signaling cascade that eliminates the target cell, or (b) instructs the target cell to differentiate to a specific effector function. In some embodiments, the method is for immunotherapy. In some embodiments, the target cell is an autoreactive T cell.

The present invention also features vectors encoding MHCRs of the present invention. The present invention also features vectors encoding SCRs of the present invention.

Then present invention also features an engineered cell co-expressing on its surface a chimeric receptor (MHCR) comprising a major histocompatibility complex (MHC) portion derived from an extracellular domain of a mammalian MHC protein directly or indirectly linked to a transmembrane domain of a T cell receptor (TCR) portion derived from a mammalian TCR protein, wherein the MHC portion is N-terminal to the TCR portion; and a surrogate coreceptor (SCR) comprising a cell surface receptor ligand portion indirectly linked to a signaling molecule portion by a transmembrane domain, wherein the signaling molecule portion has kinase or phosphatase activity. The MHCR may be adapted to bind to a TCR of a target cell and the SCR may be adapted to bind to a cell surface receptor of the target cell.

The present invention also features an engineered T-cell co-expressing on its surface: a chimeric receptor (MHCR) comprising a major histocompatibility complex (MHC) portion derived from an extracellular domain of a mammalian MHC protein directly or indirectly linked to a transmembrane domain of a T cell receptor (TCR) portion derived from a mammalian TCR protein, the MHC portion being N-terminal to the TCR portion, the MHC portion being selected from HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB beta, H2-EK alpha, and H2-EK beta, the TCR portion being selected from TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, TCC4; and a surrogate coreceptor (SCR) comprising a cell surface receptor ligand portion indirectly linked to a signaling molecule portion by a transmembrane domain, the signaling molecule portion having kinase or phosphatase activity. The MHCR may be adapted to bind to a TCR of a target cell and the SCR may be adapted to bind to a cell surface receptor of the target cell.

In some embodiments, the MHC molecule comprises at least a portion of an extracellular domain of a MHC protein. In some embodiments, the TCR molecule comprises at least a portion of a cytoplasmic domain of a TCR protein, at least a portion of a transmembrane domain of a TCR protein, at least a portion of an extracellular domain of a TCR protein, or a combination thereof. In some embodiments, the chimeric receptor is adapted to bind to a TCR. In some embodiments, the chimeric receptor is adapted to complex with at least one CD3 subunit.

The present invention also features a surrogate co-receptor (SCR) comprising a cell surface receptor ligand portion directly or indirectly fused to a signaling molecule portion via a transmembrane domain, wherein the SCR is adapted to bind to a cell surface receptor of a target cell. In some embodiments, the cell surface receptor ligand portion is indirectly fused to the signaling molecule portion via a linker.

The present invention also features genetically engineered cells (e.g., redirected cells) that express on their surfaces a chimeric receptor according to the present invention. In some embodiments, the cell is a T cell (e.g., CD8+ T cell, CD4+ T cell, etc.). In some embodiments, the cell co-expresses one or more SCRs according to the present invention. In some embodiments, the chimeric receptor is complexed with at least one CD3 subunit.

The present invention also features a method of eliminating a target cell or reprogramming a target cell (said target cell comprising a TCR). In some embodiments, the method comprises introducing a genetically engineered cell that expresses on its surface a chimeric receptor to the target cell, wherein the chimeric receptor is specific for the TCR of the target cell. In some embodiments, binding of the chimeric receptor on the genetically engineered cell to the TCR of the target cell initiates a signaling cascade that eliminates the target cell. In some embodiments, binding of the chimeric receptor of the genetically engineered cell to the TCR of the target cell instructs the target cell to differentiate to a specific effector function (e.g. Th1, Th2, Th17, Tfh, Treg or cytotoxic T cell). In some embodiments, the chimeric receptor (e.g., MHCR) is expressed on a Treg and binding of the chimeric receptor to the TCR of a target cell inhibits the target cell's function (e.g., redirect the Treg function against an autoimmune cell). In some embodiments, the genetically engineered cell co-expresses a SCR. In some embodiments, the SCR comprises a cell surface receptor ligand specific for a cell surface receptor on the target cell. In some embodiments, binding of the chimeric receptor to the TCR and binding of the cell surface receptor ligand of the SCR to the cell surface receptor of the target cell initiates a signaling cascade that eliminates the target cell, or instructs the target cell to differentiate to a specific effector function.

In some embodiments, the method is for immunotherapy. In some embodiments, the genetically engineered cell is surgically introduced to a host (e.g., a mammal). In some embodiments, the target cell is an autoreactive T cell.

The present invention also features nucleotide sequences encoding the chimeric receptors of the present invention. The present invention also features vectors encoding the chimeric receptors of the present invention. The present invention also features nucleotide sequences encoding the SCRs of the present invention. The present invention also features vectors encoding the SCRs of the present invention.

Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent application or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:

FIG. 1A shows molecules involved in T cell activation. Engagement of the TCR with pMHC (MHC with a peptide antigen) initiates T cell activation.

FIG. 1B shows the molecular components of the ✓ lpha-beta-TCR-CD3 complex. The TCR transfers pMHC-specific information to the CD3 subunits and inside the T cell. Triangles represent the inner and outer leafs of the cell membrane. Red and blue dots and ovals represent the transmembrane charge interactions that drive subunit assembly of the complexes (from Kuhns et al., 2006, Immunity 24:133-139).

FIG. 2A shows a redirected T cell expressing a MHCR (pMHCR with peptide antigen) of the present invention. The MHCR in complex with CD3 subunits is bound to a target T cell's TCR.

FIG. 2B shows non-limiting examples of MHCR configurations (and the schematics are not limiting with respect to N-terminal and C-terminal orientation). TCR refers to the T cell receptor portion; MHC refers to the major histocompatibility portion, antigen refers to the antigen portion, and L refers to a linker. The present invention is not limited to these configurations. For example, in some embodiments the antigen portion is integrated into the MHC portion. In some embodiments, the MHC portion is N-terminal to the TCR portion (see orientation of sequences below).

FIG. 3A is a schematic view of a chimeric surrogate coreceptor (SCR), e.g., one comprising CD80/CD86-Lck.

FIG. 3B shows a redirected T cell expressing a MHCR (pMHCR) and two surrogate coreceptors (SCRs). The MHCR, bound to a target T cell's TCR, is complexed with CD3. The SCRs are bound to the target T cell's coreceptors (CD28, CTLA-4). Binding of the SCRs to coreceptors on the target T cell may help initiate CD3 signaling similar to that seen in normal T cell activation.

FIG. 4 shows expression of pMHCR-CD3 complexes on T cell hybridomas. 58α⁻β⁻ cells that lack endogenous TCRs were transduced with a pMHCR composed of MCC:I-E^(k). The proportional expression (diagonal) of I-E^(k) and CD3 subunits suggests surface co-dependent expression of the epitopes.

FIG. 5 shows TCR-specific IL-2 production by pMHCR-CD3 expressing T cell hybridomas. 58α⁻β⁻ cells that lack endogenous TCRs were transduced with a pMHCR composed of MCC:I-E^(k) as well as a CD80-Lck surrogate coreceptor (SCR). The cells were co-cultured with parental M12 B cells, or M12 cells stably transduced to express the MCC:I-E^(k)-specific 2B4 TCR alone or with CD28. The increased IL-2 expression in the presence of CD28 indicates that the surrogate coreceptor (SCR) enhances pMHCR-CD3 signaling.

FIG. 6 shows TCR-specific killing of CD4 T cells by redirected CTLs. Purified CD8 T cells from B10.A mice were activated in vitro and transduced with a MCC:I-E^(k) pMHCR (agonist) or an HB:I-E^(k) pMHCR (null) as well as a CD80-Lck surrogate coreceptor. The redirected CTLs were then co-cultured at the indicated ratios with naïve ex vivo 5c.c7 TCR transgenic CD4 T cells overnight. Killing was evaluated by flow cytometry using count beads relative to the 0:1 samples.

DETAILED DESCRIPTION OF THE INVENTION

Chimeric MHC Receptors (MHCRs)

The present invention features chimeric receptors (e.g., “MHCRs”) comprising at least a MHC portion (e.g., class I, class II, non-classical, a combination thereof, etc.) and a TCR portion (e.g., αβ, γδ TCR, etc.) (see FIG. 2B(i)). For example, the MHCR may comprise a MHC portion and a TCR portion, a MHC and a TCR portion optionally separated by a linker (see FIG. 2B (iii) and (iv)). A linker may be any appropriate linker such as but not limited to a peptide linker. In some embodiments, the MHCR further comprises a peptide antigen (see FIG. 2B (ii)); a MHCR comprising a peptide antigen may herein be referred to as a “pMHCR”. Note that MHC portions and/or TCR portions may be from any appropriate species including but not limited to human, monkey, mouse, rat, rabbit, or the like, e.g., any other appropriate mammalian species. The components and configurations of the MHRCs of the present invention are not limited to those shown in FIG. 2B. For example, the MHCR may comprise a TCR portion and a MHC portion; a TCR portion and a MHC portion separated by a linker; a TCR portion and a MHC portion and an antigen portion; a TCR portion and a MHC portion and an antigen portion, wherein the TCR portion and MHC portion are separated by a linker; a TCR portion and a MHC portion and an antigen portion, wherein the MHC portion and antigen portion are separated by a linker; a TCR portion and a MHC portion and an antigen portion, wherein the TCR and MHC portion are separated by a linker and the MHC portion and the antigen portion are separate by a linker; etc.

The MHC portion may comprise one or more MHC proteins (e.g., HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1), one or more fragments thereof, or combinations thereof. For reference, non-limiting MHC sequences (human, mouse) are listed below in Table 1.1 and Table 1.2. Note that MHC genes are highly polymorphic, and thus the present invention is not limited to the sequences in Table 1.1 And Table 1.2. The present invention includes MHC polymorphisms and any other appropriate variant of MHC proteins.

TABLE 1.1 Examples of Human MHC Protein Sequences SEQ ID NO. Description Amino Acid Sequence 1 Uniprot P01891 MAVMAPRTLV LLLSGALALT QTWAGSHSMR HLA-A gene YFYTSVSRPG RGEPRFIAVG YVDDTQFVRF (MHC I) DSDAASQRME PRAPWIEQEG PEYWDRNTRN VKAQSQTDRV DLGTLRGYYN QSEAGSHTIQ MMYGCDVGSD GRFLRGYRQD AYDGKDYIAL KEDLRSWTAA DMAAQTTKHK WEAAHVAEQW RAYLEGTCVE WLRRYLENGK ETLQRTDAPK THMTHHAVSD HEATLRCWAL SFYPAEITLT WQRDGEDQTQ DTELVETRPA GDGTFQKWVA VVVPSGQEQR YTCHVQHEGL PKPLTLRWEP SSQPTIPIVG IIAGLVLFGA VITGAVVAAV MWRRKSSDRK GGSYSQAASS DSAQGSDVSL TACKV 2 Uniprot P18464 MRVTAPRTVL LLLWGAVALT ETWAGSHSMR HLA-B gene YFYTAMSRPG RGEPRFIAVG YVDDTQFVRF (MHC I) DSDAASPRTE PRAPWIEQEG PEYWDRNTQI FKTNTQTYRE NLRIALRYYN QSEAGSHTWQ TMYGCDVGPD GRLLRGHNQY AYDGKDYIAL NEDLSSWTAA DTAAQITQRK WEAAREAEQL RAYLEGLCVE WLRRHLENGK ETLQRADPPK THVTHHPVSD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP SSQSTIPIVG IVAGLAVLAV VVIGAVVATV MCRRKSSGGK GGSYSQAASS DSAQGSDVSL TA 3 Uniprot Q29963 MRVMAPRTLI LLLSGALALT ETWACSHSMR HLA-C gene YFDTAVSRPG RGEPRFISVG YVDDTQFVRF (MHC I) DSDAASPRGE PRAPWVEQEG PEYWDRETQK YKRQAQADRV NLRKLRGYYN QSEDGSHTLQ WMYGCDLGPD GRLLRGYDQS AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAAREAEQW RAYLEGTCVE WLRRYLENGK ETLQRAEHPK THVTHHPVSD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PEPLTLRWEP SSQPTIPIVG IVAGLAVLAV LAVLGAVMAV VMCRRKSSGG KGGSCSQAAS SNSAQGSDES LIACKA 4 Uniprot P20036 MRPEDRMFHI RAVILRALSL AFLLSLRGAG HLA DPA1 AIKADHVSTY AAFVQTHRPT GEFMFEFDED (MHC II) EMFYVDLDKK ETVWHLEEFG QAFSFEAQGG LANIAILNNN LNTLIQRSNH TQATNDPPEV TVFPKEPVEL GQPNTLICHI DKFFPPVLNV TWLCNGELVT EGVAESLFLP RTDYSFHKFH YLTFVPSAED FYDCRVEHWG LDQPLLKHWE AQEPIQMPET TETVLCALGL VLGLVGIIVG TVLIIKSLRS GHDPRAQGTL 5 Uniprot P04440 MMVLQVSAAP RTVALTALLM VLLTSVVQGR HLA DPB1 ATPENYLFQG RQECYAFNGT QRFLERYIYN (MHC II) REEFARFDSD VGEFRAVTEL GRPAAEYWNS QKDILEEKRA VPDRMCRHNY ELGGPMTLQR RVQPRVNVSP SKKGPLQHHN LLVCHVTDFY PGSIQVRWFL NGQEETAGVV STNLIRNGDW TFQILVMLEM TPQQGDVYTC QVEHTSLDSP VTVEWKAQSD SARSKTLTGA GGFVLGLIIC GVGIFMHRRS KKVQRGSA 6 Uniprot P01909 MILNKALMLG ALALTTVMSP CGGEDIVADH HLA DQA1 VASYGVNLYQ SYGPSGQYTH EFDGDEQFYV (MHC II) DLGRKETVWC LPVLRQFRFD PQFALTNIAV LKHNLNSLIK RSNSTAATNE VPEVTVFSKS PVTLGQPNIL ICLVDNIFPP VVNITWLSNG HSVTEGVSET SFLSKSDHSF FKISYLTLLP SAEESYDCKV EHWGLDKPLL KHWEPEIPAP MSELTETVVC ALGLSVGLVG IVVGTVFIIR GLRSVGASRH QGPL 7 Uniprot P01920 MSWKKALRIP GGLRAATVTL MLAMLSTPVA HLA DQB1 EGRDSPEDFV YQFKAMCYFT NGTERVRYVT (MHC II) RYIYNREEYA RFDSDVEVYR AVTPLGPPDA EYWNSQKEVL ERTRAELDTV CRHNYQLELR TTLQRRVEPT VTISPSRTEA LNHHNLLVCS VTDFYPAQIK VRWFRNDQEE TTGVVSTPLI RNGDWTFQIL VMLEMTPQHG DVYTCHVEHP SLQNPITVEW RAQSESAQSK MLSGIGGFVL GLIFLGLGLI IHHRSQKGLL H 8 Uniprot P01903 MAISGVPVLG FFIIAVLMSA QESWAIKEEH VIIQAEFYLN HLA DRA gene PDQSGEFMFD FDGDEIFHVD MAKKETVWRL (MHC II) EEFGRFASFE AQGALANIAV DKANLEIMTK RSNYTPITNV PPEVTVLTNS PVELREPNVL ICFIDKFTPP VVNVTWLRNG KPVTTGVSET VFLPREDHLF RKFHYLPFLP STEDVYDCRV EHWGLDEPLL KHWEFDAPSP LPETTENVVC ALGLTVGLVG IIIGTIFIIK GVRKSNAAER RGPL 9 Uniprot Q30167 MVCLRLPGGS CMAVLTVTLM VLSSPLALAG HLA DRB1 gene DTRPRFLEEV KFECHFFNGT ERVRLLERRV (MHC II) HNQEEYARYD SDVGEYRAVT ELGRPDAEYW NSQKDLLERR RAAVDTYCRH NYGVGESFTV QRRVQPKVTV YPSKTQPLQH HNLLVCSVNG FYPGSIEVRW FRNGQEEKTG VVSTGLIQNG DWTFQTLVML ETVPQSGEVY TCQVEHPSVM SPLTVEWRAR SESAQSKMLS GVGGFVLGLL FLGAGLFIYF RNQKGHSGLP PTGFLS

TABLE 1.2 Examples of Mouse MHC Protein Sequences SEQ ID NO. Description Amino Acid Sequence 10 Uniprot Q9TQ72 RSRALILGVL ALTTMLSLCG GEDYIEADHV MHC II antigen IE AFYGISVYQS PGDIGQYTFE FDGDELFYVD alpha (H2-Aa) LDKKETVWML PEFGQLTSFD PQGGLQEIAT GKYNLEILIK DSNFTPAANE APQATVFPKS PVLLGQPNTL ICFVDNIFPP VINITWLRNS KSVTDGVYET SFLVNRDHSF HKLSYLTFIP SDDDIYDCKV EHWGLEEPVL KHWEPEIPAP MSELTETVIC ALGLSVGLVG IVVGTIFIIQ GLRSGGTSRH 11 Uniprot O19440 MAQRTLFLLL AAALTMIETR AGPHSMRYFE MHC I antigen TAVFRPGLGE PRFISVGYVD NTQFVSFDSD (H2-B1) AENPRSEPRA PWMEQEGPEY WERETQIAKD NEQSFGWSLR NLIHYYNQSK GGFHTFQRLS GCDMGLDGRL LRGYLQFAYD GRDYITLNED LKTWMAADLV ALITRRKWEQ AGAAELYKFY LEGECVEWLR RYLELGNETL LRTDPPKAHV THHPRPAGDV TLRCWALGFY PADITLTWQL NGEELTQDME LVETRPAGDG TFQKWAAVVV PLGKEQNYTC HVYHEGLPEP LTLRWEPPPS TGSNMVNIAV LVVLGAVIII EAMVAFVLKS SRKIAILPGP AGTKGSSAS 12 Uniprot Q31191 MAPCTLLLLL AAALAPTQTR AARAAARGPV MHC I H2-K gene RRSGSHRAPP PGPHSLSDAD NPRFEPRAPW (Haplotype d) MEQEGPEYWE EQTQRAKSDE QWFRVSLRTA (H2-K1) QRYYNQSKGG SHTFQRMFGC DVGSDWRLLR GYQQFAYDGR DYIALNEDLK TWTAADTAAL ITRRKWEQAG DAEYYRAYLE GECVEWLRRY LELGNETLLR TDSPKAHVTY HPRSQVDVTL RCWALGFYPA DITLTWQLNG EDLTQDMELV ETRPAGDGTF QKWAAVVVPL GKEQNYTCHV HHKGLPEPLT LRWKLPPPTV SNTVIIAVLV VLGAAIVTGA VVAFVMKMRR NTGGKGVNYA LAPGSQTSDL SLPDGKVMVH 13 Uniprot P04230 MVWLPRVPCV AAVILLLTVL SPPMALVRDS H2 Class II RPWFLEYCKS ECHFYNGTQR VRLLERYFYN histocompatibility LEENLRFDSD VGEFHAVTEL GRPDAENWNS antigen E-B beta QPEFLEQKRA EVDTVCRHNY EISDKFLVRR chain RVEPTVTVYP TKTQPLEHHN LLVCSVSDFY PGNIEVRWFR NGKEEKTGIV STGLVRNGDW TFQTLVMLET VPQSGEVYTC QVEHPSLTDP VTVEWKAQST SAQNKMLSGV GGFVLGLLFL GAGLFIYFRN QKGQSGLQPT GLLS 14 Uniprot P04224 MATIGALVLR FFFIAVLMSS QKSWAIKEEH MHC II E-K alpha TIIQAEFYLL PDKRGEFMFD FDGDEIFHVD chain IEKSETIWRL EEFAKFASFE AQGALANIAV (underlined portion is DKANLDVMKE RSNNTPDANV APEVTVLSRS portion used in SEQ PVNLGEPNIL ICFIDKFSPP VVNVTWLRNG ID NO: 30) RPVTEGVSET VFLPRDDHLF RKFHYLTFLP STDDFYDCEV DHWGLEEPLR KHWEFEEKTL LPETKENVVC ALGLFVGLVG IVVGIILIMK GIKKRNVVER RQGAL 15 GenBank ID: MWLPRVPCVAAVILLLTVLSPPVALVRDSRPWFLEY M36939.1 CKSECHFYNGTQRVRLLVRYFYNLEENLRFDSDV MHC II E-K beta GEFRAVTELGRPDAENWNSQPEFLEQKRAEVD chain TVCRHNYEIFDNFLVPRRVEPTVWYPTKTQPLEH (underlined portion is HNLLVCSVSDFYPGNIEVRWFRNGKEEKTGIVSTG used in SEQ ID NO: LVRNGDVVTFQTLVMLETVPQSGEVYTCQVEHPSL 31, 32) TDPVTVEWKAQSTSAQNKMLSGVGGFVLGLLFLG AGLFIYFRNQKGQSGLQPTGLLS

Referring to Table 1.1, the HLA-A (MHC 1) sequence (SEQ ID NO: 1) includes the signal peptide (amino acids 1-24); amino acids 25-308 are believed to make up the extracellular region, amino acids 309-332 are believed to make up the transmembrane region, and amino acids 333-365 are believed to make up the cytoplasmic region. The HLA-B (MHC 1) sequence (SEQ ID NO: 2) includes the signal peptide (amino acids 1-24); amino acids 25-308 are believed to make up the extracellular region, amino acids 309-332 are believed to make up the transmembrane region, and amino acids 333-362 are believed to make up the cytoplasmic region. The HLA-C(MHC 1) sequence (SEQ ID NO: 3) includes the signal peptide (amino acids 1-24); amino acids 25-308 are believed to make up the extracellular region, amino acids 309-333 are believed to make up the transmembrane region, and amino acids 334-366 are believed to make up the cytoplasmic region. The HLA DPA1 (MHC II) sequence (SEQ ID NO: 4) includes the signal peptide (amino acids 1-28); amino acids 29-222 are believed to make up the extracellular region, amino acids 223-245 are believed to make up the transmembrane region, and amino acids 246-260 are believed to make up the cytoplasmic region. The HLA DPB1 (MHC II) sequence (SEQ ID NO: 5) includes the signal peptide (amino acids 1-29); amino acids 30-225 are believed to make up the extracellular region, amino acids 226-246 are believed to make up the transmembrane region, and amino acids 247-258 are believed to make up the cytoplasmic region. The HLA DQA1 (MHC 11) sequence (SEQ ID NO: 6) includes the signal peptide (amino acids 1-23); amino acids 24-216 are believed to make up the extracellular region, amino acids 217-239 are believed to make up the transmembrane region, and amino acids 240-254 are believed to make up the cytoplasmic region. The HLA DQB1 (MHC II) sequence (SEQ ID NO: 7) includes the signal peptide (amino acids 1-32); amino acids 33-230 are believed to make up the extracellular region, amino acids 231-251 are believed to make up the transmembrane region, and amino acids 252-261 are believed to make up the cytoplasmic region. The HLA DRA (MHC II) sequence (SEQ ID NO: 8) includes the signal peptide (amino acids 1-25); amino acids 26-216 are believed to make up the extracellular region, amino acids 217-239 are believed to make up the transmembrane region, and amino acids 240-254 are believed to make up the cytoplasmic region. The HLA DRB1 (MHC II) sequence (SEQ ID NO: 9) includes the signal peptide (amino acids 1-29); amino acids 30-227 are believed to make up the extracellular region, amino acids 228-250 are believed to make up the transmembrane region, and amino acids 251-266 are believed to make up the cytoplasmic region. The MHC E-K alpha chain (SEQ ID NO: 14) includes the signal peptide (aa 1-25), the extracellular domain (aa 26-216), the transmembrane domain (aa 217-24), and a cytoplasmic portion (aa 243-255).

As previously discussed, the MHCR of the present invention comprises at least a MHC portion and a TCR portion. In some embodiments, a MHC portion comprises one or more MHC proteins (e.g., HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, MHC E-K alpha, MHC E-K beta, etc.), fragments thereof, or combinations thereof. For example, in some embodiments, the MHC portion comprises a fragment of any of SEQ ID NO: 1-15.

In some embodiments, the MHC portion comprises a peptide that is at least 80% identical to a MHC protein or a fragment thereof. In some embodiments, the MHC portion comprises a peptide that is at least 85% identical to a MHC protein or a fragment thereof. In some embodiments, the MHC portion comprises a peptide that is at least 90% identical to a MHC protein or a fragment thereof. In some embodiments, the MHC portion comprises a peptide that is at least 95% identical to a MHC protein or a fragment thereof. In some embodiments, the MHC portion comprises a peptide that is at least 99% identical to a MHC protein or a fragment thereof.

In some embodiments, a fragment of a MHC protein is from 10 to 25 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 50 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 100 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 150 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 200 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 250 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 300 aa in length. In some embodiments, a fragment of a MHC protein is from 10 to 350 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 50 as in length. In some embodiments, a fragment of a MHC protein is from 25 to 100 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 150 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 200 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 250 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 300 aa in length. In some embodiments, a fragment of a MHC protein is from 25 to 350 aa in length. In some embodiments, a fragment of a MHC protein is from 50 to 100 aa in length. In some embodiments, a fragment of a MHC protein is from 50 to 150 aa in length. In some embodiments, a fragment of a MHC protein is from 50 to 200 aa in length. In some embodiments, a fragment of a MHC protein is from 50 to 250 aa in length. In some embodiments, a fragment of a MHC protein is from 50 to 300 as in length. In some embodiments, a fragment of a MHC protein is from 50 to 350 aa in length. In some embodiments, a fragment of a MHC protein is from 100 to 150 aa in length. In some embodiments, a fragment of a MHC protein is from 100 to 200 aa in length. In some embodiments, a fragment of a MHC protein is from 100 to 250 aa in length. In some embodiments, a fragment of a MHC protein is from 100 to 300 as in length. In some embodiments, a fragment of a MHC protein is from 100 to 350 aa in length. In some embodiments, a fragment of a MHC protein is from 150 to 200 aa in length. In some embodiments, a fragment of a MHC protein is from 150 to 250 aa in length. In some embodiments, a fragment of a MHC protein is from 150 to 300 as in length. In some embodiments, a fragment of a MHC protein is from 150 to 350 aa in length. In some embodiments, a fragment of a MHC protein is from 200 to 250 as in length. In some embodiments, a fragment of a MHC protein is from 200 to 300 as in length. In some embodiments, a fragment of a MHC protein is from 200 to 350 as in length. In some embodiments, a fragment of a MHC protein is from 250 to 300 aa in length. In some embodiments, a fragment of a MHC protein is from 250 to 350 as in length. In some embodiments, a fragment of a MHC protein is more than 350 aa in length.

A TCR portion may comprise one or more TCR proteins (e.g., TCRA, TCRB), one or more fragments thereof, or combinations thereof. For reference, non-limiting TCR sequences (human and mouse) are listed below in Table 2.1 and Table 2.2. The present invention is not limited to the TCR sequences in Table 2.1 and Table 2.2.

TABLE 2.1 Examples of Human TCR Protein Sequences SEQ ID NO. Description Amino Acid Sequence 16 Uniprot P01848 PNIQNPDPAV YQLRDSKSSD KSVCLFTDFD T cell receptor SQTNVSQSKD SDVYITDKTV LDMRSMDFKS alpha chain NSAVAWSNKS DFACANAFNN SIIPEDTFFP constant region SPESSCDVKL VEKSFETDTN LNFQNLSVIG (TRAC, TCRA) FRILLLKVAG FNLLMTLRLW SS 17 Uniprot P01850 EDLNKVFPPE VAVFEPSEAE ISHTQKATLV T cell receptor CLATGFFPDH VELSWWVNGK EVHSGVSTDP beta-1 chain QPLKEQPALN DSRYCLSSRL RVSATFWQNP constant region RNHFRCQVQF YGLSENDEWT QDRAKPVTQI (TRBC1) VSAEAWGRAD CGFTSVSYQQ GVLSATILYE ILLGKATLYA VLVSALVLMA MVKRKDF 18 Uniprot A0A5B9 DLKNVFPPEV AVFEPSEAEI SHTQKATLVC T cell receptor LATGFYPDHV ELSWWVNGKE beta-2 chain VHSGVSTDPQ PLKEQPALND SRYCLSSRLR constant region VSATFWQNPR NHFRCQVQFY (TRBC2, GLSENDEWTQ DRAKPVTQIV SAEAWGRADC TCRBC2) GFTSESYQQG VLSATILYEI LLGKATLYAV LVSALVLMAM VKRKDSRG 19 Uniprot B7Z8K6 SQPHTKPSVF VMKNGTNVAC LVKEFYPKDI T cell receptor RINLVSSKKI TEFDPAIVIS PSGKYNAVKL delta chain GKYEDSNSVT CSVQHDNKTV HSTDFEVKTD constant region STDHVKPKET ENTKQPSKSC HKPKAIVHTE (TRDC) KVNMMSLTVL GLRMLFAKTV AVNFLLTAKL FFL 20 Uniprot P0CF51 DKQLDADVSP KPTIFLPSIA ETKLQKAGTY T cell receptor LCLLEKFFPD VIKIHWQEKK SNTILGSQEG gamma-1 chain NTMKTNDTYM KFSWLTVPEK SLDKEHRCIV constant region RHENNKNGVD QEIIFPPIKT DVITMDPKDN (TRGC1) CSKDANDTLL LQLTNTSAYY MYLLLLLKSV VYFAIITCCL LRRTAFCCNG EKS 21 Uniprot P03986 DKQLDADVSP KPTIFLPSIA ETKLQKAGTY T cell receptor LCLLEKFFPD IIKIHWQEKK SNTILGSQEG gamma-2 chain NTMKTNDTYM KFSWLTVPEE SLDKEHRCIV constant region RHENNKNGID QEIIFPPIKT DVTIVDPKDS (TRGC2, YSKDANDVIT MDPKDNWSKD ANDTLLLQLT TCRGC2) NTSAYYMYLL LLLKSVVYFA IITCCLLGRT AFCCNGEKS

TABLE 2.2 Examples of Mouse TCR Protein Sequences SEQ ID NO. Description Amino Acid Sequence 22 Uniprot P01849 PYIQNPEPAV YQLKDPRSQD STLCLFTDFD T cell receptor alpha SQINVPKTME SGTFITDKTV LDMKAMDSKS chain constant region NGAIAWSNQT SFTCQDIFKE TNATYPSSDV (TCRA-mouse) PCDATLTEKS FETDMNLNFQ NLSVMGLRIL (underlined portion LLKVAGFNLL MTLRLWSS refers to sequence also used in SEQ ID NO: 30) 23 Uniprot P01852 EDLRNVTPPK VSLFEPSKAE IANKQKATLV T cell receptor beta-1 CLARGFFPDH VELSWWVNGK EVHSGVSTDP chain constant region QAYKESNYSY CLSSRLRVSATFWHNPRNHF (TCB1-mouse) RCQVQFHGLS EEDKWPEGSP KPVTQNISAE AWGRADCGIT SASYQQGVLS ATILYEILLG KATLYAVLVS TLVVMAMVKR KNS 24 Uniprot P01851 EDLRNVTPPK VSLFEPSKAE IANKQKATLV T cell receptor beta-2 CLARGFFPDH VELSWWVNGK EVHSGVSTDP chain constant region QAYKESNYSY CLSSRLRVSA TFWHNPRNHF (TCB2-mouse) RCQVQFHGLS EEDKWPEGSP KPVTQNISAE (underlined portion AWGRADCGIT SASYHQGVLS ATILYEILLG refers to sequence used KATLYAVLVS GLVLMAMVKK KNS in SEQ ID NO: 31, 32) 25 Uniprot P01853 DKRLDADISP KPTIFLPSVA ETNLHKTGTY T cell receptor gamma LCLLEKFFPD VIRVYWKEKN GNTILDSQEG chain constant region DTLKTKGTYM KFSWLTVPER AMGKEHSCIV C10.5 (TCC1-mouse) KHENNKGGAD QEIFFPSIKK VATTCWQDKN DVLQFQFTST SAYYTYLLLL LKSVIYLAII SFSLLRRTSV CGNEKKS 26 Uniprot P03985 DKKLDADISP KPTIFLPSVA ETNLHKTGTY T cell receptor gamma LCVLEKFFPD VIRVYWKEKK GNTILDSQEG chain constant region DMLKTNDTYM KFSWLTVPER SMGKEHRCIV C7.5 (TCC2-mouse) KHENNKGGAD QEIFFPTIKK VAVSTKPTTC WQDKNDVLQL QFTITSAYYT YLLLLLKSVI YLAIISFSLL RRTSVCCNEK KS 27 Uniprot P06334 PSDKRLDADI SPKPTIFLPS VAETNLHKTG T cell receptor gamma TYLCILEKFF PDVIRVYWKD KNGNTILDSQ chain constant region EGDTLKTKGT YMKFSWLTVP ERSMGKEHRC DFL12 (TCC3-mouse) IVKHENNKGG ADQEIFFPSI KKVATTCWQD KNDVLQLQFM STSAYYTYLL LLLKSVIYLA IISFSLLRRT SVCCNEKRS 28 Uniprot P06335 DKRTDSDFSP KPTIFLPSAA ETNLHKAGTY T cell receptor gamma LCLLEKFFPK VIRVYWKEKD GEKILESQEG chain constant region NTIKTNDRYM KFSWLTVTED SMAKEHSCIV 5/10-13 (TCC4-mouse) KHENNKRGVD QEILFPPIGK AFTTINVNPR DSVLRHENVN NATDLEDCMK GRKDMLQLQV TTTYAFYTYL ILFFKSMVHL AFVVFCLFRR AAMSCDDQRS

Referring to the TRAC protein (SEQ ID NO: 16) in Table 2, amino acids 118-137 are believed to make up the transmembrane domain, and amino acids 138-142 are believed to make up the cytoplasmic domain. Referring to the TRBC1 protein (SEQ ID NO: 17) in Table 2, amino acids 151-171 are believed to make up the transmembrane domain. Referring to the TRBC2 protein (SEQ ID NO: 18) in Table 2, amino acids 145-167 are believed to make up the transmembrane domain. Referring to the TRDC protein (SEQ ID NO: 19) in Table 2, amino acids 130-152 are believed to make up the transmembrane domain. Referring to the TRGC1 protein (SEQ ID NO: 20) in Table 2, amino acids 139-161 are believed to make up the transmembrane domain. Referring to the TRGC2 protein (SEQ ID NO: 21) in Table 2, amino acids 157-177 are believed to make up the transmembrane domain, and amino acids 178-189 are believed to make up the cytoplasmic domain.

As previously discussed, the MHCR of the present invention comprises at least a MHC portion and a TCR portion. In some embodiments, a TCR portion comprises one or more TCR proteins (e.g., TRAC, TRBC1, TRBC2, TRDC, TRCG1, TRCG2, TCRA-mouse, TCB1-mouse, TCB2-mouse, TCC1-mouse, TCC2-mouse, TCC3 mouse, TCC4 mouse, etc.), fragments thereof, or combinations thereof. For example, in some embodiments, the TCR portion comprises a fragment of any of SEQ ID NO: 16-28. (In some embodiments, the fragment is from 5 to 10 aa in length. In some embodiments, the fragment is from 10 to 20 aa in length, in some embodiments, the fragment is from 10 to 30 aa in length. IN some embodiments, the fragment is from 10 to 40 aa in length. In some embodiments, the fragment is from 10 to 50 aa in length, etc.

In some embodiments, the TCR portion comprises a peptide that is at least 80% identical to a TCR protein (e.g., any of SEQ ID NO: 16-28), or a fragment thereof. In some embodiments, the TCR portion comprises a peptide that is at least 85% identical to a TCR protein (e.g., any of SEQ ID NO: 16-28), or a fragment thereof. In some embodiments, the TCR portion comprises a peptide that is at least 90% identical to a TCR protein (e.g., any of SEQ ID NO: 16-28), or a fragment thereof. In some embodiments, the TCR portion comprises a peptide that is at least 95% identical to a TCR protein (e.g., any of SEQ ID NO: 16-28), or a fragment thereof. In some embodiments, the TCR portion comprises a peptide that is at least 99% identical to a TCR protein (e.g., any of SEQ ID NO: 16-28), or a fragment thereof.

In some embodiments, a fragment of a TCR protein is from 10 to 25 aa in length. In some embodiments, a fragment of a TCR protein is from 10 to 50 as in length. In some embodiments, a fragment of a TCR protein is from 10 to 100 aa in length. In some embodiments, a fragment of a TCR protein is from 10 to 150 aa in length. In some embodiments, a fragment of a TCR protein is from 25 to 50 aa in length. In some embodiments, a fragment of a TCR protein is from 25 to 100 aa in length. In some embodiments, a fragment of a TCR protein is from 25 to 150 aa in length. In some embodiments, a fragment of a TCR protein is from 50 to 100 aa in length. In some embodiments, a fragment of a TCR protein is from 50 to 150 aa in length. In some embodiments, a fragment of a TCR protein is from 100 to 150 as in length. In some embodiments, a fragment of a TCR protein is more than 150 aa in length.

In some embodiments, the MHCR comprises a peptide antigen. Any appropriate peptide antigen may be used. The peptide antigen in the pMHCR complex directs the specificity of the pMHCR molecule, therefore the pMHCR molecule will be specific for T cells with TCRs that are specific for that peptide antigen/pMHCR. A non-limiting example of a peptide antigen that may be used with the MHCR is moth cytochrome c peptide (aa 88-103, ANERADLIAYLKQATK (SEQ ID NO: 29)). The peptide antigens used in the Examples (see below) are peptides commonly used as model antigens in mouse models. Any appropriate peptide antigen may be used, and the present invention is not limited to the peptide antigens disclosed herein. For example, in some embodiments, the peptide antigen comprises any immunodominant peptide antigen identified to bind a class I or class 11 MHC. In some embodiments, the peptide antigen comprises any immunodominant peptide antigen identified to bind a class I or class II MHC and elicit a response. A response may include but is not limited to an autoimmune response, an allergic response, an asthma response, or an inappropriate Treg response. The peptide antigen may be any appropriate length.

In some embodiments, the MHCR comprises at least a portion of a MHC molecule that allows for binding to an appropriate TCR. In some embodiments, the MHCR comprises at least a portion of a MHC molecule that allows for binding to an appropriate TCR and at least a portion of a TCR molecule (e.g., a portion of a TCR molecule that allows for appropriate signaling and/or complexing subunits such as CD3 subunits). In some embodiments, the MHCR comprises a transmembrane domain that is at least partially derived from (i) a MHC molecule, (ii) a TCR molecule, or (iii) both the MHC molecule and TCR molecule. In some embodiments, the MHCR comprises a transmembrane domain, wherein a portion (or all) of the transmembrane domain is not derived from a MHC molecule or a TCR molecule. In some embodiments, the MHCR comprises an extracellular domain that is at least partially derived from (i) a MHC molecule, (ii) a TCR molecule, or (iii) both the MHC molecule and TCR molecule. In some embodiments, the MHCR comprises an extracellular domain, wherein a portion of the extracellular domain is not derived from a MHC molecule or a TCR molecule.

As an example, in some embodiments, the MHCR comprises at least a portion of the extracellular domain of a MHC molecule (e.g., the extracellular domain of HLA-DRA) and at least a portion of the transmembrane domain of a TCR molecule and at least a portion of the cytoplasmic domain of a TCR molecule. As another example, in some embodiments, the MHCR comprises at least a portion of the extracellular domain of a TCR molecule.

The present invention also features redirected cells, such as redirected T cells, expressing MHCRs of the present invention, e.g., as described above. Without wishing to limit the present invention to any theory or mechanism, the MHCRs are generally adapted to recognize and bind to appropriate (specific) TCRs. In some embodiments, the MHCR is expressed in a CD8+ T cell (e.g., a cytotoxic T cell, T_(C) cells, CTLs). In some embodiments, the MHCR is expressed in a CD4+ T cell (e.g., a T helper cell, T_(H) cell or a regulatory T cell (Treg cell)). The present invention is not limited to the expression of MHCRs in T cells, nor is the present invention limited to expression of MHCRs in CD8+ or CD4+ T cells, e.g., the MHCRs may be expressed in CD8+/CD4+ thymocytes, γδT cells, NK cells, NK T cells, etc. In some embodiments, the MHCR of the redirected T cell complexes or is adapted to complex with CD3 subunits (e.g., forming a MHCR-CD3 complex).

In some embodiments, the MHCR comprises a MHC portion derived from an extracellular portion of a MHC protein and a TCR portion derived from a transmembrane domain of a TCR protein. In some embodiments, the MHC portion and TCR portion are directly linked. In some embodiments, the MHC portion and TCR portion are separated by a linker. In some embodiments, the linker comprises a glycine-rich linker.

The present invention is not limited to the MHC portions and TCR portions described herein. For example, the MHC portion may comprise any MHC peptide, e.g., an extracellular domain (or a portion thereof) of any MHC peptide. The TCR portion may comprise any TCR peptide, e.g., a transmembrane domain (or portion thereof) of any TCR peptide. Further, the present invention is not limited to antigens, signaling molecules, and cell surface receptor ligands described herein, e.g., the present invention may be applicable to a wide range of MHC molecules, TCR molecules, antigens, signaling molecules cell surface receptor ligands, etc.

Surrogate Coreceptors (SCRs)

The present invention also features chimeric surrogate coreceptors (SCR), e.g., receptors that recruit signaling molecules (e.g., kinases such as but not limited to Src kinases (e.g., Lck), phosphatases, etc.). In some embodiments, the SRCs recruit signaling molecules (e.g., kinases) to the MHCR and/or CD3 subunits. The present invention also features cells expressing a SCR. In some embodiments, redirected cells, e.g., redirected T cells, express both a MHCR and a SCR. In some embodiments, cells express more than one type of SCR. Without wishing to limit the present invention to any theory or mechanism, it is believed that certain SCRs may enhance signaling through the pMHCR-CD3 complex.

In some embodiments, the SCR comprises a cell surface receptor ligand (e.g., T cell surface receptor ligand) fused to a signaling molecule (e.g., kinase (e.g., Lck or other appropriate kinase), phosphatase, etc.). In some embodiments, the cell surface receptor ligand and the kinase are separated by a linker, e.g., a peptide linker or any other appropriate linker. The signaling molecule is not limited to a kinase or a phosphatase.

In some embodiments, the cell surface receptor ligand (e.g., T cell surface receptor ligand) comprises CD80, CD86, fragments thereof, or combinations thereof. The present invention is not limited to CD80 and CD86; any other appropriate cell surface receptor ligand (or a fragment thereof) may be used. For example, in some embodiments, the cell surface receptor ligand comprises a CD28 ligand, a CTLA-4 ligand, an ICOS ligand, an OX40 ligand, a PD-1 ligand (e.g., PD-1L), a CD2 ligand, etc.

As an example, in some embodiments, when a T cell is expressing a pMHCR (a MHCR with a peptide antigen), the pMHCR may complex with CD3 subunits, forming a pMHCR-CD3 complex. If the cell is also expressing a CD80-Lck SCR, then when the pMHCR binds a TCR on a target T cell, the CD80-Lck may also bind to CD28 on the same target T cell. Without wishing to limit the present invention to any theory or mechanism, it is believed that then the CD80-Lck SCR should recruit Lck to the pMHCR-CD3 complex to phosphorylate the pMHCR-CD3 ITAMs for robust signaling.

In some embodiments, the SCR is engineered (e.g., a particular cell surface receptor ligand of the SCR is selected) to target a specific set of target cells. For example, T follicular helper cells express a molecule called PD-1 and these cells provide help to B cells to make autoantibodies in autoimmune diseases such as Lupus. The ligand for PD-1 is PD-1L, so a SCR comprising PD-1L and Lck may be co-expressed with a pMHCR recognized by the TCR of the T follicular helper cell. This may allow for targeting of this specific T follicular helper cell population.

The present invention also features methods of use of said MHCRs, SCRs, and/or said redirected cells, for example for immunotherapy. In some embodiments, the redirected cells may eliminate autoreactive T cells, regulatory T cells (Tregs) that protect tumor cells by suppressing anti-tumor T cell responses, or any other appropriate T cell. For example, in some embodiments, the MHCR is an auto-antigen MHCR, and the MHCR's target is an autoreactive T cell.

Examples

Example 1: Redirected T cells targeting CD4 T Helper Cells. Example 1 describes a non-limiting experimental approach to target CD4 T cells. A prototype pMHCR was engineered with a peptide antigen: the moth cytochrome c peptide (SEQ ID NO: 29) was fused to the mouse class II MHC I-E^(k) (MCC:I-E^(k); e.g., see SEQ ID NO: 31). This pMHCR was expressed (e.g., retrovirally expressed) in T cell hybridomas. It was determined that this pMHCR (e.g., pMHCR-CD3 complex) was expressed on the surface of T cell hybridomas (see FIG. 4). IL-2 production was induced after interactions with cognate TCRs (e.g., 5c.c7, 2B4), yet an irrelevant peptide (control peptide antigen) in the pMHCR-CD3 complex rendered it non-stimulatory (data not shown).

Lck fusions were generated with known ligands for T cell surface receptors. For example, all T cells express CD28. Lck fusions with CD28 ligands (e.g., CD80, CD86) were engineered to generate surrogate coreceptors (SCRs), e.g., CD80-Lck (see SEQ ID NO: 33, SEQ ID NO: 38), e.g., CD86-Lck (see SEQ ID NO: 34, SEQ ID NO: 39). When the pMHCR-CD3 complex was co-expressed with SCR CD80-Lck in hybridomas, these cells produced significantly more IL-2 in response to cells expressing the 2B4 TCR ligand+CD28 than they did in response to cells expressing only the 284 TCR ligand (see FIG. 5). This suggested that signaling through the pMHCR-CD3 complex could be augmented through the use of a SCR.

MCC:IE^(k) pMHCR-CD3 and the SCR CD80-Lck or HB:IE^(k) pMHCR-CD3 (e.g., see SEQ ID NO: 32) and the SCR CD80-Lck were expressed in in vitro differentiated CD8 cytotoxic T cells (CTLs) and their ability to kill 5c.c7 TCR transgenic CD4 T cells expressing the TCR specific for the MCC:IE^(k) pMHCR was evaluated. Surface expression of the pMHCRs on the redirected CTLs was observed, suggesting that these chimeric receptor modules compete with the endogenous TCR for assembly with the endogenous CD3 subunits (data not shown). CTLs expressing the MCC:IE^(k) pMHCR robustly killed the target CD4 T cells while those expressing the null HB:IE^(k) pMHCR did not (see FIG. 6). This suggests that CD8 T cells can be redirected to target and eliminate antigen-specific CD4 T cells.

Example 2: Redirected T cells targeting CD4 T Helper Cells in Allergic Asthma. Example 2 describes a non-limiting experimental approach to target CD4 T helper cells involved in allergic asthma, e.g., to help eliminate naïve Der p 1-specific CD4 T cells from the repertoire prior to House Dust Mite (HDM) sensitization. Without wishing to limit the present invention to any theory or mechanism, it is believed that eliminating allergen-specific CD4 T cells from the repertoire may help prevent the onset of T_(H)2 immunity upon HDM sensitization.

A pMHCR (pMHCR-CD3 complex) will be retrovirally expressed in in vitro activated CTLs. The pMHCR will bear a pMHCR comprising either the immunodominant HDM-derived Der p 1 epitope (aa117-127) in the context of I-A^(b) (Derp1:IA^(b)) or the immunodominant West Nile Virus peptide from the envelope protein (aa641-655) in the context of I-A^(b) (E641:IA^(b)). The E641:IA^(b) pMHCR cells will serve as a non-specific control population.

The in vitro activated CTLs will also be transduced with a CD80-Lck SCR to enhance signaling. These redirected CTLs will then be transferred intravenously into C57Bl/6 mice to target and eliminate Derp1:IA^(b)- or E641:IA^(b)-specific naïve CD4 T cells from the endogenous repertoire. After a certain length of time, e.g., 1 week, the elimination of antigen-specific CD4 T cells will be evaluated. This will be performed via tetramer enrichment experiments using a Derp1:IA^(b) tetramer and a E641:IA^(b) tetramer. The presence of the redirected CD8 T cells will also be assessed by flow cytometry by gating on CD3+CD8+IA^(b)+ T cells since mouse T cells do not express class II MHC.

After determining if the redirected CTLs eliminate the target population, mice that received redirected CTLs one-week prior will be sensitized with HDM (e.g., intranasally, e.g., with HDM extracts). This will be done even if endogenous CD4 T cells specific for Derp1:IA^(b) are detected, but only if redirected T cells are still present in the mice. This may help to determine if activation of the CD4 T cells made them more susceptible to targeting by the redirected CTLs.

Example 3: Redirected T cells targeting CD4 T Helper Cells in Lungs After Sensitization. Example 3 describes a non-limiting experimental approach to target CD4 T helper cells in lungs of HDM-sensitized mice. Without wishing to limit the present invention to any theory or mechanism, it is believed that eliminating allergen-specific CD4 T cells from the lungs of HDM-sensitized mice may help attenuate T_(H)2 immunity.

Der p 1-specific CD4 T cells will be targeted similarly to Example 2, but only after HDM sensitization. In brief, mice will be sensitized with HDM according to the protocol described above. They will then receive redirected Derp1:IA^(b) or E641:IA^(b) pMHCR-CD3 CTLs on day 14. Various surrogate co-receptors will be employed to explore the efficacy of the technology and approach. For example, the CD80-Lck fusion SCR will be used, as well as others, e.g., a TIM-4-Lck SCR (since the TIM-1 expressed on CD4 T cells is genetically linked with asthma and this combination for targeting might enhance effectiveness). One week after transfer of redirected CTLs, cytokine and cellular analysis will be performed as described above in Example 2 so as to assess the impact of these cells on the lung cytokine milieu and cellularity. The status of the redirected CTLs will also be evaluated.

Example 4: Attenuation of Der p 1-specific CD4 T cell function in situ. Example 4 describes a non-limiting experimental approach to redirect Tregs against Der p 1-specific CD4 T cells. Without wishing to limit the present invention to any theory or mechanism, it is believed that this may help attenuate function of said CD4 T cells and help diminish T_(H)2 immunity.

In vitro generated induced Tregs (iTregs) expressing a MHCR will be tested for efficacy in reducing HDM-induced airway hypersensitivity. Induced Tregs (iTregs) will be generated in vitro and transduced with pMHCR and SCRs as described in Examples 2 and 3 above. These cells will then either be transferred prior to HDM sensitization as in Example 2 or after sensitization as in Example 3. Evaluation of the lung cytokine milieu and cellularity will then be performed as described above.

Table 3 shows examples of protein sequences for reagents the above examples. Table 4 shows the nucleotide sequences for the proteins in Table 3. Note that in SEQ ID NO: 30, a portion is derived from SEQ ID NO: 14 and a portion is derived from SEQ ID NO: 22. In SEQ ID NO: 31, a portion is derived from SEQ ID NO: 15, a portion is derived from SEQ ID NO: 23, and a portion is derived from SEQ ID NO: 29 (and other residues may correspond to a glycine-rich linking region). In SEQ ID NO: 32, a portion is derived from SEQ ID NO: 15 and a portion is derived from SEQ ID NO: 23 (and other residues may correspond to a glycine-rich linking region).

TABLE 3 Peptide sequences for reagents in Examples. SEQ ID NO. Description Amino Acid Sequence 30 I-E^(k)α-TCRα MATIGALLLRFFFIAVLMSSQKSWAIKEEHTIIQAEFY Note: underlined LLPPKRGEFMFDFDGDEIFHVDIEKSETIWRLEEFA portion is from SEQ KFASFEAQGALANIAVDKANLDVMKERSNNTPDAN ID NO: 14 (MHC VAPEVTVLSRSPVNLGEPNILICFIDKFSPPVVNVIW portion), bold portion FRNGRPVTEGVSETVFLPRDDHLFRKFHYLTFLPST is from SEQ ID NO: DDFYDCEVDHWGLEEPLRKHWEFEEKTLLPETKE 22 (TCR portion) CDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAG FNLLMTLRLWSS 31 MCC: I-E^(k)β-TCRβ MVWLPRVPCVAAVILLLTVLSPPVALVRDSGS ANER (note: italic portion ADLIAYLKQATKEFRSGGGGSLVPRGSGGGGSVDR shows peptide PWFLEYCKSECHFYNGTQRVRLLVRYFYNLEENLR antigen sequence, FDSDVGEFRAVTELGRPDAENWNSQPEFLEQKRA underlined portion is EVDTVCRHNYEIFDNFLVPRRVEPTVIVYPTKTQPL from SEQ ID NO: 15 EHHNLLVCSVSDFYPGNIEVRWFRNGKEEKTGIVS (MHC portion), and TGLVRNGDWTFQTLVMLETVPQSGEVYTCQVEHP bold portion is from SLTDPVTVEWKAQSTSAQNK CGITSASYHQGVLSA SEQ ID NO: 24 (TCR TILYEILLGKATLYAVLVSGLVLMAMVKKKNSAAA portion) 32 HB: I-E^(k)β-TCRβ MVWLPRVPCVAAVILLLTVLSPPVALVRDSGSGKKVI Note: italic portion TAFNEGLKEFRSGGGGSLVPRGSGGGGSVDRPWF shows peptide LEYCKSECHFYNGTQRVRLLVRYFYNLEENLRFDS antigen sequence, DVGEFRAVTELGRPDAENWNSQPEFLEQKRAEVD underlined portion is TVCRHNYEIFDNFLVPRRVEPTVIVYPTKTQPLEHH from SEQ ID NO: 15 NLLVCSVSDFYPGNIEVRWFRNGKEEKTGIVSTGLV (MHC portion), and RNGDWTFQTLVMLETVPQSGEVYTCQVEHPSLTD bold portion is from PVTVEWKAQSTSAQNK CGITSASYHQGVLSATILY SEQ ID NO: 24 (TCR EILLGKATLYAVLVSGLVLMAMVKKKNSAAA portion) 33 CD80-Lck MACNCQLMQDTPLLKFPCPRLILLFVLLIRLSQVSS (mCD80-mLck DVDEQLSKSVKDKVLLPCRYNSPHEDESEDRIYWQ fusion) KHDKVVLSVIAGKLKVWPEYKNRTLYDNTTYSLIILG LVLSDRGTYSCVVQKKERGTYEVKHLALVKLSIKAD FSTPNITESGNPSADTKRITCFASGGFPKPRFSWLE NGRELPGINTTISQDPESELYTISSQLDFNTTRNHTI KCLIKYGDAHVSEDFTWEKPPEDPPDSKNTLVLFG AGFGAVITVVVIVVIIKCFCKHRSCFRRNEASRETNN SLTFGPEEALAEQTVFLTTSHYPIVPLDSKISLPIRNG SEVRDPLVTYEGSLPPASPLQDNLVIALHSYEPSHD GDLGFEKGEQLRILEQSGEVVWKAQSLTTGQEGFIP FNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNT HGSFLIRESESTAGSFSLSVRDFDQNQGEWKHYKI RNLDNGGFYISPRITFPGLHDLVRHYTNASDGLCTK LSRPCQTQKPQKPVVWEDEWEVPRETLKLVERLGA GQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLA EANLMKQLQHPRLVRLYAVVTQEPIYIITEYMENGSL VDFLKTPSGIKLNVNKLLDMAAQIAEGMAFIEEQNYI HRDLRAANILVSDTLSCKIADFGLARLIEDNEYTARE GAKFPIKWTAPEAINYGTFTIKSDVWSFGILLTEIVTH GRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYH LMMLCWKERPEDRPTFDYLRSVLDDFFTATEGQY QPQPGT 34 CD86-Lck MDPRCTMGLAILIFVTVLLISDAVSVETQAYFNGTAY (mCD86-mLck LPCPFTKAQNISLSELVVFWQDQQKLVLYEHYLGTE fusion) KLDSVNAKYLGRTSFDRNNWTLRLHNVQIKDMGSY DCFIQKKPPTGSIILQQTLTELSVIANFSEPEIKLAQN VTGNSGINLTCTSKQGHPKPKKMYFLITNSTNEYGD NMQISQDNVTELFSISNSLSLSFPDGVWHMTVVCV LETESMKISSKPLNFTQEFPSPQTYWKEITASVTVAL LLVMLLIIVCHKKPNQPSRPSNTASKLERDSNADRE TINLKELEPQIASAKPNAECTSHYPIVPLDSKISLPIR NGSEVRDPLVTYEGSLPPASPLQDNLVIALHSYEPS HDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEG FIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPG NTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKH YKIRNLDNGGFYISPRITFPGLHDLVRHYTNASDGL CTKLSRPCQTQKPQKPWWEDEWEVPRETLKLVER LGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPD AFLAEANLMKQLQHPRLVRLYAVVTQEPIYIITEYME NGSLVDFLKTPSGIKLNVNKLLDMAAQIAEGMAFIE EQNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNE YTAREGAKFPIKWTAPEAINYGTFTIKSDVWSFGILL TEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNC PEELYHLMMLCWKERPEDRPTFDYLRSVLDDFFTA TEGQYQPQPGT

TABLE 4 Examples of DNA sequences for encoding the proteins in Table 3. SEQ ID NO. Description Gene Sequence 35 I-E^(k)α-TCRα aataagcttctcgagcgccaccATGGCCACAATTGGAGCCCTGCTGTTAAGATTT fusion TTCTTCATTGCTGTTCTGATGAGCTCCCAGAAGTCATGGGCTATCAAAG AGGAACACACCATCATCCAGGCGGAGTTCTATCTTTTACCAGACAAACG TGGAGAGTTTATGTTTGACTTTGACGGCGATGAGATTTTCCATGTAGAC ATTGAAAAGTCAGAGACCATCTGGAGACTTGAAGAATTTGCAAAGTTTG CCAGCTTTGAGGCTCAGGGTGCACTGGCTAATATAGCTGTGGACAAAG CTAACCTGGATGTCATGAAAGAGCGTTCCAACAACACTCCAGATGCCA ACGTGGCCCCAGAGGTGACTGTACTCTCCAGAAGCCCTGTGAACCTG GGAGAGCCCAACATCCTCATCTGTTTCATTGACAAGTTCTCCCCTCCA GTGGTCAATGTCACCTGGTTCCGGAATGGACGGCCTGTCACCGAAGG CGTGTCAGAGACAGTGTTTCTCCCGAGGGACGATCACCTCTTCCGCAA ATTCCACTATCTGACCTTCCTGCCCTCCACAGATGATTTCTATGACTGTG AGGTGGATCACTGGGGTTTGGAGGAGCCTCTGCGGAAGCACTGGGAG TTTGAAGAGAAAACCCTCCTCCCAGAAACTAAAGAGtgtgatgccacgttgacc gagaaaaGCTTTGAAACAGATATgaacctaaactttcaaaacctgtcaGTTATGGGAC TCCGAATCCtcctgctgaaagtagcgggatttaacCTGCTCATGACGCTgaggctgtggt ccagttgaggatccgcta 36 MCC: I-E^(k)β-T aatCTCGAGCGCCACCATGGTGTGGCTCCCCAGAGTTCCCTGTGTGGC CRβ fusion AGCTGTGATCCTGTTGCTGACAGTGCTGAGCCCTCCAGTGGCTTTGGT CAGAGACTCCGGATCCGCCAACGAGAGGGCCGACCTGATCGCCTACC TGAAGCAGGCCACCAAGGAATTCAGATCCGGAGGCGGAGGCTCCCTG GTGCCTCGGGGCTCCGGAGGCGGAGGCTCCGTCGACAGACCATGGT TTTTGGAATACTGTAAATCTGAGTGTCATTTCTACAACGGGACGCAGCG CGTGCGGCTTCTGGTAAGATACTTCTACAACCTGGAGGAGAACCTGCG CTTCGACAGCGACGTGGGCGAGTTCCGCGCGGTGACCGAGCTGGGG CGGCCAGACGCCGAGAACTGGAACAGCCAGCCGGAGTTCCTGGAGC AAAAGCGGGCCGAGGTGGACACGGTGTGCAGACACAACTATGAGATC TTCGATAACTTCCTTGTGCCGCGGAGAGTTGAGCCTACGGTGACTGTG TACCCCACAAAGACGCAGCCCCTGGAACACCACAACCTCCTGGTCTG CTCTGTGAGTGACTTCTACCCTGGCAACATTGAAGTCAGATGGTTCCG GAATGGCAAGGAGGAGAAAACAGGAATTGTGTCCACGGGCCTGGTCC GAAATGGAGACTGGACCTTCCAGACACTGGTGATGCTGGAGACGGTT CCTCAGAGTGGAGAGGTTTACACCTGCCAGGTGGAGCATCCCAGCCT GACCGACCCTGTCACGGTCGAGTGGAAAGCACAGTCCACATCTGCAC AGAACAAGtgtggaatcactagtgcatcctatcatcagggggttctgtctgcaaccatcctctatgag atcctactggggaaggccaccctatatgctgtgctggtcagtggcctagtgctgatgGCCATGGTC AAGAAAAAAAATTCCgcggccgcatgatgagatctgagctccatagaggcg 37 HB: I-E^(k)β-TC aatCTCGAGCGCCACCATGGTGTGGCTCCCCAGAGTTCCCTGTGTGGC Rβ fusion AGCTGTGATCCTGTTGCTGACAGTGCTGAGCCCTCCAGTGGCTTTGGT CAGAGACTCCGGATCCGGCAAGAAGGTGATCACCGCCTTCAACGAGG GCCTGAAGGAATTCAGATCCGGAGGCGGAGGCTCCCTGGTGCCTCGG GGCTCCGGAGGCGGAGGCTCCGTCGACAGACCATGGTMTGGAATA CTGTAAATCTGAGTGTCATTTCTACAACGGGACGCAGCGCGTGCGGCT TCTGGTAAGATACTTCTACAACCTGGAGGAGAACCTGCGCTTCGACAG CGACGTGGGCGAGTTCCGCGCGGTGACCGAGCTGGGGCGGCCAGAC GCCGAGAACTGGAACAGCCAGCCGGAGTTCCTGGAGCAAAAGCGGG CCGAGGTGGACACGGTGTGCAGACACAACTATGAGATCTTCGATAACT TCCTTGTGCCGCGGAGAGTTGAGCCTACGGTGACTGTGTACCCCACA AAGACGCAGCCCCTGGAACACCACAACCTCCTGGTCTGCTCTGTGAG TGACTTCTACCCTGGCAACATTGAAGTCAGATGGTTCCGGAATGGCAA GGAGGAGAAAACAGGAATTGTGTCCACGGGCCTGGTCCGAAATGGAG ACTGGACCTTCCAGACACTGGTGATGCTGGAGACGGTTCCTCAGAGT GGAGAGGTTTACACCTGCCAGGTGGAGCATCCCAGCCTGACCGACCC TGTCACGGTCGAGTGGAAAGCACAGTCCACATCTGCACAGAACAAGtgt ggaatcactagtgcatcctatcatcagggggttctgtctgcaaccatcctctatgagatcctactggggaa ggccaccctatatgctgtgctggtcagtggcctagtgctgatgGCCATGGTCAAGAAAAAAA ATTCCgcggccgcatgatgagatctgagctccatagaggcg 38 CD80-Lck acgtctagatacctcgaggccaccATGGCTTGCAATTGTCAGttgatgcaggatacaccact (mCD80-mL cctcaagtttccatgtccaaggctcattcttctctttgtgctgctgattcgtctttcacaagtgtcttcagatgttg ck fusion) atgaacaactgtccaagtcagtgaaagataaggtattgctgccttgccgttacaactctcctcatgaagat gagtctgaagaccgaatctactggcaaaaacatgacaaagtggtgctgtctgtcattgctgggaaacta aaagtgtggcccgagtataagaaccggactttatatgacaacactacctactctcttatcatcctgggcct ggtcctttcagaccggggcacatacagctgtgtcgttcaaaagaaggaaagaggaacgtatgaagtta aacacttggctttagtaaagttgtccatcaaagctgacttctctacccccaacataactgagtctggaaac ccatctgcagacactaaaaggattacctgctttgcttccgggggtttcccaaagcctcgcttctcttggttgg aaaatggaagagaattacctggcatcaatacgacaatttcccaggatcctgaatctgaattgtacaccat tagtagccaactagatttcaatacgactcgcaaccacaccattaagtgtctcattaaatatggagatgctc acgtgtcagaggacttcacctgggaaaaacccccagaagaccctcctgatagcaagaacacacttgt gctctttggggcaggattcggcgcagtaataacagtcgtcgtcatcgttgtcatcatcaaatgcttctgtaa gcacagaagctgtttcagaagaaatgaggcaagcagagaaacaaacaacagccttaccttcgggcc tgaagaagcattagctGAACAGACCGTCTTCCTTaccactagtCACTATCCCATAGT Cccactggacagcaagatctcgctgcccatccggaatggctctgaagtgcgggacccactggtcacct atgagggatctctcccaccagcatccccgctgcaagacaacctggttatcgccctgcacagttatgagc cctcccatgatggagacttgggctttgagaagggtgaacagctccgaatcctggagcagagcggtgag tggtggaaggctcagtccctgacgactggccaagaaggcttcattcccttcaacttcgtggcgaaagca aacagcctggagcctgaaccttggttcttcaagaatctgagccgtaaggacgccgagcggcagcttttg gcgcccgggaacacgcatggatccttcctgatccgggaaagcgaaagcactgcggggtccttttccctg tcggtcagagacttcgaccagaaccagggagaagtggtgaaacattacaagatccgtaacctagaca acggtggcttctacatctcccctcgtatcacttttcccggattgcacgatctagtccgccattacaccaacgc ctctgatgggctgtgcacaaagttgagccgtccttgccagacccagaagccccagaaaccatggtggg aggacgaatgggaagttcccagggaaacactgaagttggtggagcggctgggagctggccagttcgg ggaagtgtggatggggtactacaacggacacacgaaggtggcggtgaagagtctgaaacaaggga gcatgtcccccgacgccttcctggctgaggctaacctcatgaagcagctgcagcacccgcggctagtcc ggctttatgcagtggtcacccaggaacccatctacatcatcacggaatacatggagaacgggagccta gtagattttctcaagactccctcgggcatcaagttgaatgtcaacaaacttttggacatggcagcccagatt gcagagggcatggcgttcatcgaagaacagaattacatccatcgggacctgcgcgccgccaacatcc tggtgtctgacacgctgagctgcaagattgcagactttggcctggcgcgcctcattgaggacaatgagta cacggcccgggagggggccaaatttcccattaagtggacagcaccagaagccattaactatgggacc ttcaccatcaagtcagacgtgtggtccttcgggatcttgcttacagagatcgtcacccacggtcgaatccct tacccaggaatgaccaaccctgaagtcattcagaacctggagagaggctaccgcatggtgagacctg acaactgtccggaagagctgtaccacctcatgatgctgtgctggaaggagcgcccagaggaccggcc cacgtttgactaccttcggagtgttctggatgacttcttcacagccacagagggcCAGTACCAGCC CCAGCCTggtacctagtgagaattctacatg 39 CD86-Lck tactctagatacctcgaggccaccATGGACCCCAGATGCACCatgggcttggcaatccttatc (mCD86-mL tttgtgacagtcttgctgatctcagatgctgtttccgtggagacgcaagcttatttcaatgggactgcatatct ck fusion) gccgtgcccatttacaaaggctcaaaacataagcctgagtgagctggtagtattttggcaggaccagca aaagttggttctgtacgagcactatttgggcacagagaaacttgatagtgtgaatgccaagtacctgggc cgcacgagctttgacaggaacaactggactctacgacttcacaatgttcagatcaaggacatgggctcg tatgattgttttatacaaaaaaagccacccacaggatcaattatcctccaacagacattaacagaactgtc agtgatcgccaacttcagtgaacctgaaataaaactggctcagaatgtaacaggaaattctggcataaa tttgacctgcacgtctaagcaaggtcacccgaaacctaagaagatgtattttctgataactaattcaacta atgagtatggtgataacatgcagatatcacaagataatgtcacagaactgttcagtatctccaacagcct ctctctttcattcccggatggtgtgtggcatatgaccgttgtgtgtgttctggaaacggagtcaatgaagattt cctccaaacctctcaatttcactcaagagtttccatctcctcaaacgtattggaaggagattacagcttcag ttactgtggccctcctccttgtgatgctgctcatcattgtatgtcacaagaagccgaatcagcctagcaggc ccagcaacacagcctctaagttagagcgggatagtaacgctgacagagagactatcaacctgaagg aacttgaaccccaaattgcttcagcaaaaccaaatgcagagtgtactagtCACTATCCCATAGT Cccactggacagcaagatctcgctgcccatccggaatggctctgaagtgcgggacccactggtcacct atgagggatctctcccaccagcatccccgctgcaagacaacctggttatcgccctgcacagttatgagc cctcccatgatggagacttgggctttgagaagggtgaacagctccgaatcctggagcagagcggtgag tggtggaaggctcagtccctgacgactggccaagaaggcttcattcccttcaacttcgtggcgaaagca aacagcctggagcctgaaccttggttcttcaagaatctgagccgtaaggacgccgagcggcagcttttg gcgcccgggaacacgcatggatccttcctgatccgggaaagcgaaagcactgcggggtccttttccctg tcggtcagagacttcgaccagaaccagggagaagtggtgaaacattacaagatccgtaacctagaca acggtggcttctacatctcccctcgtatcacttttcccggattgcacgatctagtccgccattacaccaacgc ctctgatgggctgtgcacaaagttgagccgtccttgccagacccagaagccccagaaaccatggtggg aggacgaatgggaagttcccagggaaacactgaagttggtggagcggctgggagctggccagttcgg ggaagtgtggatggggtactacaacggacacacgaaggtggcggtgaagagtctgaaacaaggga gcatgtcccccgacgccttcctggctgaggctaacctcatgaagcagctgcagcacccgcggctagtcc ggctttatgcagtggtcacccaggaacccatctacatcatcacggaatacatggagaacgggagccta gtagattttctcaagactccctcgggcatcaagttgaatgtcaacaaacttttggacatggcagcccagatt gcagagggcatggcgttcatcgaagaacagaattacatccatcgggacctgcgcgccgccaacatcc tggtgtctgacacgctgagctgcaagattgcagactttggcctggcgcgcctcattgaggacaatgagta cacggcccgggagggggccaaatttcccattaagtggacagcaccagaagccattaactatgggacc ttcaccatcaagtcagacgtgtggtccttcgggatcttgcttacagagatcgtcacccacggtcgaatccct tacccaggaatgaccaaccctgaagtcattcagaacctggagagaggctaccgcatggtgagacctg acaactgtccggaagagctgtaccacctcatgatgctgtgctggaaggagcgcccagaggaccggcc cacgtttgactaccttcggagtgttctggatgacttcttcacagccacagagggcCAGTACCAGCC CCAGCCTggtacctagtgagaattctacatg

The disclosures of the following U.S. patents are incorporated in their entirety by reference herein: U.S. Pat. Application No. 20140219975; U.S. Pat. Nos. 8,450,112; 7,741,465; 6,319,494; CA 2209300; CA 2104957; EP 0574512; U.S. Pat. Nos. 6,407,221; 6,268,411; U.S. Pat. Application No. 20040258697; EP 1292621; EP 2659893; WO 2011101681; WO 2005054292; EP 1379670; U.S. Pat. Nos. 6,056,952; 6,410,319; 8,524,234; 7,871,817.

As used herein, the term “about” refers to plus or minus 10% of the referenced number.

Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in the present application is incorporated herein by reference in its entirety.

Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments, descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting of” is met. 

What is claimed is:
 1. An engineered cell, comprising: a. A chimeric receptor module (MHCR) that comprises: i) an extracellular domain of a major histocompatibility complex (MHC); ii) a T-cell receptor (TCR) portion comprising a transmembrane domain of a TCR, and a cytoplasmic domain of a TCR; and b. A surrogate coreceptor (SCR) that comprises: i) an extracellular region of a cell surface receptor ligand; ii) a transmembrane region; and iii) a kinase.
 2. The engineered cell of claim 1, wherein the extracellular domain of the MHC is directly bound to the TCR portion.
 3. The engineered cell of claim 1, wherein an antigenic peptide is bound to the extracellular domain of the MHC.
 4. The engineered cell of claim 1, wherein the extracellular domain of the MHC is derived from an MHC selected from the group consisting of: HLA-A, HLA-B, HLA-C, Beta2-microglobulin, HLA-DPA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB beta, H2-EK alpha, and H2-EK beta.
 5. The engineered cell of claim 1, wherein the transmembrane domain and the cytoplasmic domain of the TCR are derived from a TCR selected from the group consisting of: TRAC, TRBC1, TRBC2, TRDC, TRGC1, and TRGC2.
 6. The engineered cell of claim 1, wherein the cell surface receptor ligand is a T-cell surface receptor ligand.
 7. The engineered cell of claim 1, wherein the T-cell surface receptor ligand is selected from the group consisting of: a CD28 ligand, a CTLA-4 ligand, an ICOS ligand, an OX40 ligand, and a CD2 ligand.
 8. The engineered cell of claim 1, wherein the T-cell surface receptor ligand is selected from the group consisting of: CD80 and CD86.
 9. The engineered cell of claim 1, wherein the kinase is a Src kinase.
 10. The engineered cell of claim 9, wherein said Src kinase is Lck or Fyn.
 11. The engineered cell of claim 6, wherein the T-cell surface ligand is CD80, and the kinase is Lck.
 12. The engineered cell of claim 6, wherein the T-cell surface ligand is CD86, and the kinase is Lck.
 13. The engineered cell of claim 1, wherein said engineered cell is a T cell, NK cell, or NK T cell. 